Both in Biotechnology
Recursion Pharmaceuticals vs ADMA Biologics
Over the past year RXRX returned −22.4% and ADMA returned −28.4%; their daily moves had a correlation of 0.22.
RXRX −22.4% ADMA −28.4%Growth of $1, one year, split-adjusted
| Metric | RXRX | ADMA |
|---|---|---|
| Price | $3.88 | $10.48 |
| Market cap | $2.32B | $2.35B |
| Today | +5.43% | −5.67% |
| 1 month | −16.2% | +2.9% |
| 6 months | +13.1% | +4.0% |
| Year to date | −5.1% | −42.5% |
| 1 year | −28.7% | −31.8% |
| Revenue growth (YoY) | +258.5% | +2.0% |
| Gross margin | 45.9% | 69.4% |
| Net margin | −641.6% | 30.4% |
| P/E (TTM) | — | 13.9× |
| Price / sales | 34.0× | 4.6× |
| Net cash | $538.0M | -$60.6M |
| Dividend yield | — | — |
| Volatility (60d) | 95.9% | 40.3% |
| Short % of float | 37.5% | 9.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).